GeneOne Life Science Inc (011000) - Total Liabilities
Based on the latest financial reports, GeneOne Life Science Inc (011000) has total liabilities worth ₩70.19 Billion KRW (≈ $47.56 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 011000 cash generation efficiency to assess how effectively this company generates cash.
GeneOne Life Science Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how GeneOne Life Science Inc's total liabilities have evolved over time, based on quarterly financial data. Check 011000 financial resilience to evaluate the company's liquid asset resilience ratio.
GeneOne Life Science Inc Competitors by Total Liabilities
The table below lists competitors of GeneOne Life Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grazziotin S.A
SA:CGRA3
|
Brazil | R$355.82 Million |
|
Land and Houses Freehold and Leasehold Property Fund
BK:LHPF
|
Thailand | ฿185.80 Million |
|
Broad Capital Acquisition Corp Unit
NASDAQ:BRACU
|
USA | $13.30 Million |
|
Nsys Co. Ltd.
KQ:333620
|
Korea | ₩34.37 Billion |
|
Optomed PLC
HE:OPTOMED
|
Finland | €6.95 Million |
|
Springwater Special Situations Corp
NASDAQ:SWSS
|
USA | $2.90 Million |
|
Selic Corp Public Company Limited
BK:SELIC
|
Thailand | ฿1.43 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down GeneOne Life Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of GeneOne Life Science Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneOne Life Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneOne Life Science Inc (2009–2024)
The table below shows the annual total liabilities of GeneOne Life Science Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩65.73 Billion ≈ $44.54 Million |
+66.33% |
| 2023-12-31 | ₩39.52 Billion ≈ $26.78 Million |
-4.53% |
| 2022-12-31 | ₩41.40 Billion ≈ $28.05 Million |
-6.01% |
| 2021-12-31 | ₩44.04 Billion ≈ $29.85 Million |
+15.71% |
| 2020-12-31 | ₩38.06 Billion ≈ $25.79 Million |
+40.49% |
| 2019-12-31 | ₩27.09 Billion ≈ $18.36 Million |
+36.24% |
| 2018-12-31 | ₩19.89 Billion ≈ $13.48 Million |
+118.67% |
| 2017-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-69.49% |
| 2016-12-31 | ₩29.81 Billion ≈ $20.20 Million |
+261.22% |
| 2015-12-31 | ₩8.25 Billion ≈ $5.59 Million |
+36.74% |
| 2014-12-31 | ₩6.03 Billion ≈ $4.09 Million |
-25.58% |
| 2013-12-31 | ₩8.11 Billion ≈ $5.50 Million |
-38.66% |
| 2012-12-31 | ₩13.22 Billion ≈ $8.96 Million |
+98.26% |
| 2011-12-31 | ₩6.67 Billion ≈ $4.52 Million |
-16.81% |
| 2010-12-31 | ₩8.02 Billion ≈ $5.43 Million |
-58.48% |
| 2009-12-31 | ₩19.30 Billion ≈ $13.08 Million |
-- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more